As the cost of obesity treatment remains a concern for patients across the United States, a new federal initiative is creating another pathway for some Medicare beneficiaries to access certain medications. The Medicare GLP-1 Bridge, launched July 1, 2026, offers eligible beneficiaries access to select GLP-1 medications for weight management at a $50 monthly copayment. The temporary program is scheduled to run through December 31, 2027, highlighting an ongoing challenge in health care: receiving a prescription does not always mean a patient can afford to fill it. Glucagon-like peptide-1, or GLP-1, medications work by acting on pathways involved in appetite, digestion and blood sugar regulation. Certain medications in this class are approved for chronic weight management, while others are used to treat conditions such as type 2 diabetes or reduce cardiovascular risks in specific patients. These medications are not interchangeable, and eligibility depends on the drug, its approved use and a patient’s health history.

For people living with obesity, treatment decisions can involve more than a conversation with a clinician. Medication prices, insurance restrictions, prior authorization requirements and limited access to health care services can affect whether a recommended treatment is within reach. These challenges are especially important to consider when addressing racial and ethnic health disparities.

The Centers for Disease Control and Prevention reported that, in August 2021 through August 2023, approximately 40.3% of U.S. adults had obesity. Earlier national data from 2017 through March 2020 showed that obesity prevalence was highest among non-Hispanic Black adults, at 49.9%, followed by Hispanic adults, at 45.6%. These figures come from different survey periods and methods, but they underscore the importance of equitable access to prevention, diagnosis and treatment. The data do not mean that obesity affects every community in the same way or that race itself determines an individual’s health. Instead, they reinforce the need to address the broader circumstances that influence health outcomes. For communities of color, the discussion around obesity care must include the ability to obtain evidence-based treatment without stigma or unnecessary financial hardship. Access to regular primary care, affordable prescriptions, nutritious food and opportunities for physical activity can vary across communities. When patients encounter barriers to treatment, a prescription alone cannot resolve them.

The National Minority Quality Forum (NMQF), through its Empowered to Heal campaign and it’s Health Not Hype campaign, emphasizes the importance of understanding obesity as a complex chronic disease rather than a personal failure. That approach supports conversations about respectful, evidence-based care and the barriers that can prevent patients from receiving it. Programs that reduce medication costs may help some people, but their impact depends on whether patients qualify, understand the requirements and can navigate the process.

Who may Qualify for the Medicare GLP-1 Bridge?

The Medicare GLP-1 Bridge is not a universal discount program for everyone who wants a GLP-1 medication. It is a temporary federal demonstration for eligible Medicare Part D beneficiaries who meet specific insurance and clinical requirements. According to CMS, qualifying beneficiaries must have an eligible standalone Medicare prescription drug plan or a qualifying Medicare Advantage plan with prescription drug coverage. A health care provider must also submit a prior authorization request confirming that the patient meets the program’s criteria. The clinical requirements include being at least 18 years old and meeting specified body mass index (BMI) and health criteria at the time GLP-1 treatment began. In general, patients must have had a BMI of at least 35, or a BMI of at least 30 alongside certain conditions, including heart failure with preserved ejection fraction, uncontrolled hypertension or stage 3a or more advanced chronic kidney disease. Another eligibility pathway applies to patients with a BMI of at least 27 who have qualifying conditions, including prediabetes, a previous heart attack, a previous stroke or symptomatic peripheral artery disease. The prescribed medication must be used for weight reduction and maintenance alongside ongoing lifestyle changes consistent with its approved labeling.

The program currently includes Foundayo, Wegovy in injection and tablet forms, and Zepbound KwikPen. Other formulations of Zepbound are not included under the demonstration. Because drug coverage and program rules can change, patients should confirm the current list with Medicare or their health care provider before making treatment decisions. Eligible participants pay $50 for a monthly supply. However, beneficiaries should understand that this copayment operates outside the standard Medicare Part D benefit. The Part D deductible does not apply, the payment does not count toward the beneficiary’s Part D out-of-pocket spending threshold, and the program does not provide the Low-Income Subsidy for eligible beneficiaries who otherwise receive that assistance. These details may affect how patients plan for other prescription costs.

Patients should speak with their prescribing clinician and confirm their eligibility through Medicare. They can also call 1-800-MEDICARE for assistance. Asking whether a plan qualifies, which medications are covered, what documentation is needed and whether other out-of-pocket expenses apply can help patients make informed decisions. Those who do not qualify should ask about other coverage options rather than assume that all GLP-1 access programs follow the same rules.

The Medicare GLP-1 Bridge represents a step toward addressing the cost of certain weight-management medications, but a temporary program cannot resolve every barrier to obesity care. For communities that experience unequal access to health services, lasting progress will require clear information, respectful conversations between patients and providers, and policies that make evidence-based treatment more attainable. As NMQF’s Health Not Hype campaign continues to elevate obesity awareness and reduce stigma, the central question remains whether patients can access the care they need—not simply whether a treatment can be prescribed.